Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks
Researchers said neither the side effects of Xeljanz, or similar drugs appear to increase the risk of venous thromboembolism-related injuries.
Researchers said neither the side effects of Xeljanz, or similar drugs appear to increase the risk of venous thromboembolism-related injuries.
Xeljanz, Jakafi and other JAK inhibitors were linked to an increased risk of melanoma, squamous cell carcinoma and Merkel cell carcinoma
The issues come as similar drugs, like Xeljanz, face intense scrutiny over heart problems and cancer risks.